Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

In The State of CRISPR and Genome Editing virtual summit, GEN brings together an outstanding line-up of pioneers and ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...

CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a notable 25% gain over the past week, gaining traction amid an executive departure. The announcement of COO Julianne Bruno’s exit could have influenced ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Claim your 7-day free trial now. Vera Therapeutics, Inc. VERA said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in ...

Synthego, a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health, and Vita ...

April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into Vita's cell therapeutic ...

Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies. ‍ Vita Therapeutics is a biotechnology company developing state ...